Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese Infants: A Multicenter Cohort Study

NCT07382219 is registered in ClinicalTrials.gov with Han Tongyan as lead sponsor.

NCT NCT07382219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07382219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese Infants: A Multicenter Cohort Study
Lead sponsor
Han Tongyan
Phase
Observational
Overall status
Completed
Start date
August 1, 2025
Completion date
October 31, 2025
Enrollment
816 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

lower respiratory tract infections, rsv infections